Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 8/20 | 0.69 |
| ▸ | KCNK9 | Q9NPC2 | 7/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3644692 | 0.90 | KCNK3 (0.71) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL14096558 | 0.87 | ALDH1A1 (0.69) | KMT2AMEN1RXFP1MAPTALDH1A1 | |
| SCHEMBL15006333 | 0.86 | KCNK3 (0.76) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL7748140 | 0.86 | NPC1 (0.73) | KCNK3KCNK9KMT2AMEN1MAPT | |
| SCHEMBL19156827 | 0.86 | NPC1 (0.72) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL14301092 | 0.83 | SMN1; SMN2 (0.75) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL15177192 | 0.83 | NPC1 (0.67) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL4248711 | 0.83 | KCNK3 (0.81) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL19156955 | 0.83 | KCNK3 (0.66) | KCNK3KCNK9KCNH2KMT2AMEN1 | |
| SCHEMBL4253897 | 0.82 | KCNK3 (0.93) | KCNK3KCNK9KCNH2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | KCNK3 1019/4885KCNK9 1229/4885KCNH2 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.